New Research extends the Benefit of BLIS K12

New Research extends the Benefit of BLIS K12

A recent study by Canadian and Japanese researchers shows new benefits for the BLIS K12 probiotic. BLIS Technologies Ltd (NZX: BLT) has reported that this new research, published in the international journal Applied and Environmental Microbiology, further extends the broad therapeutic benefits of its oral cavity probiotic, BLIS K12.

The international research group investigated the effectiveness of BLIS K12 in laboratory testing against the yeast organism responsible for the common and painful oral infection, candidiasis or oral thrush, a condition which is more frequent in children and older individuals. The researchers reported that they were surprised however to find that BLIS K12 did not work in the typical way that BLIS K12 normally protects the mouth and throat against bacterial infection. Instead, they found that BLIS K12 prevented the candidiasis-causing yeast from sticking to the throat and mouth and therefore preventing the organism from colonising and causing a subsequent infection.

BLIS K12 has already been shown in laboratory testing to be more potent against bacteria that cause throat infection and bad-breath than other over-the-counter throat lozenges and now it adds the prevention of yeast infection to that list.

“Other throat-care lozenges and medications might have a transient effect for an hour or two, but the greatest advantage that BLIS K12 has over other oral-care treatments is that it can colonise in the mouth and throat and that means that it provides protection within the oral cavity, 24 hours a day.” According to BLIS Technologies’ CEO, Dr Barry Richardson, “The fact that an active population of the BLIS K12 probiotic can remain in the mouth and colonise it, is very important for the overall effectiveness of the probiotic because this provides round the clock protection against any invading or opportunistic organisms. This means that BLIS K12 should prevent, as well as treat candidiasis infection, however controlled clinical trials are required to confirm this effect.” Dr Richardson also commented, “The whole point of providing a 24 hour probiotic defence barrier from infec
tive agents, is that one never knows when something is going to strike. While other products do provide short-term anti-bacterial defence when you are using them, it is not practical to suck a lozenge 24 hours a day”.

Dr Richardson also indicated that BLIS Technologies, in association with its distribution partner, Stratum Nutrition (USA), will formally launching BLIS K12 in Europe at the major European ingredient show, VitaFoods in May. Prof John Tagg (academic founder and consultant) has been invited to provide updates on new research for BLIS K12 at an ENT (Ear Nose& Throat) medical specialist's meeting in Moscow, as part of the market development activities in Russia around the same time.

BLIS Technologies has nearly finalised its partnership agreement with Stratum Nutrition to market the entire BLIS range of probiotic ingredients on a global basis, with the exception of China and New Zealand. The initial probiotic ingredients which are to be marketed by Stratum Nutrition include BLIS K12 and BLIS M18. Marketing developments for all probiotic products are expected to be extended to include relevant products for companion animals such as cats and dogs, because this represents a signification component of the business for Stratum’s parent company; Novus International.

Stratum Nutrition (www.stratumnutrition.com) is a human nutrition company based in St Louis, Missouri (USA). It is a subsidiary of a major international animal health company, which was formed in 1991 as a “spinout” company of what was then Monsanto’s animal nutrition division and is now called Novus International. This business has been operating for over 20 years, in 90 countries with an annual turnover of more than US$1 billion and has a focus on animal health and human nutrition. Stratum has a small but well-defined number of products, which are backed by the extensive scientific resources and support infrastructure of Novus international.
ends

© Scoop Media